Sign In
Buy CELG
$108.24
+0 (+0%)
At Close: Jan 16, 2020
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
NEW ORLEANS, Nov. 24, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6
NEW ORLEANS, Nov. 17, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff applications in a securit
LOS ANGELES, Nov. 1, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb Company ("
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
06:44pm, Wednesday, 06'th Oct 2021
NEW YORK--(BUSINESS WIRE)--ENTWISTLE & CAPPUCCI LLP FILES A SECURITIES CLASS ACTION COMPLAINT AGAINST BRISTOL-MYERS SQUIBB COMPANY
Why the Growth Isn't Over for This Best-in-Breed Biotech Stock
08:32am, Saturday, 13'th Mar 2021
It's not getting much attention lately, but the future for Amgen looks strong.
Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene
07:21am, Thursday, 04'th Feb 2021
Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027 billion, or $4.45 a share, in the fourth quarter, wider than the loss of $1.056 billion, or 55 cents a share, posted in the year-ear
Celgene-Backed Antengene Climbs On Hong Kong Debut
10:02pm, Saturday, 21'st Nov 2020
China's influence in the global pharmaceutical industry is on the rise
Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
07:30am, Thursday, 31'st Jan 2019
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018. For the fourth quarter of 2018, net product sales were $4,036
Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018
07:30am, Monday, 01'st Oct 2018
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, October 25, 2018 at 9 a.m. ET to discuss third quarter 2018 financial a
Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018
07:30am, Monday, 02'nd Jul 2018
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, July 26, 2018 at 9 a.m. ET to discuss second quarter 2018 financial an
Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
07:30am, Monday, 09'th Apr 2018
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Friday, May 04, 2018 at 9 a.m. ET to discuss first quarter 2018 financial and op
Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
04:30pm, Tuesday, 27'th Feb 2018
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its N
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
06:30am, Monday, 22'nd Jan 2018
SUMMIT, N.J. & SEATTLE--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has a
Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018
07:30am, Wednesday, 03'rd Jan 2018
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, January 25, 2018 at 9 a.m. ET to discuss fourth quarter and full-year
